Szarmach Joanna, Włodarczyk Adam, Cubała Wiesław Jerzy, Wiglusz Mariusz Stanisław
Department of Psychiatry, Medical University of Gdańsk, Dębinki St. 7 build. 25, 80-952 Gdańsk, Poland.
Psychiatr Danub. 2017 Sep;29(Suppl 3):349-352.
Antipsychotics are a key intervention strategy in pharmacotherapy in schizophrenia. However, the benzodiazepines are often prescribed to control sleep disturbances, anxiety or hostile behaviour. There is some evidence supporting the combination therapy with antipsychotics and benzodiazepines providing beneficiary treatment effect to the psychosis in positive and negative symptom domains as well as catatonia or adverse reactions to antipsychotic drugs. In particular, in a population suffering from residual symptoms of schizophrenia, in particular anxiety, emotional flattening, being refractory to approved treatment strategies, benzodiazepines as add-on to antipsychotics seem to be an option. There is rationale for the therapeutic use for long-acting benzodiazepines as the treatment of option with limited literature indicating the use of chlordiazepoxide, and diazepam. The paper reviews the best clinical practice indications for benzodiazepines as the add-on treatment to antipsychotics in schizophrenia.
抗精神病药物是精神分裂症药物治疗中的关键干预策略。然而，苯二氮䓬类药物常用于控制睡眠障碍、焦虑或敌对行为。有一些证据支持抗精神病药物与苯二氮䓬类药物联合治疗在精神分裂症的阳性和阴性症状领域以及紧张症或抗精神病药物不良反应方面具有有益的治疗效果。特别是，在患有精神分裂症残留症状，尤其是焦虑、情感平淡且对批准的治疗策略难治的人群中，苯二氮䓬类药物作为抗精神病药物的附加用药似乎是一种选择。长效苯二氮䓬类药物作为治疗选择有其治疗依据，不过仅有有限的文献表明使用了氯氮䓬和地西泮。本文综述了苯二氮䓬类药物作为精神分裂症抗精神病药物附加治疗的最佳临床实践指征。
